Mikiko Shinozaki

Publications (7) View all

• Article: Major depressive disorder in patients with rheumatoid arthritis.

  Eri Sato, Katsuji Nishimura, Ayako Nakajima, Hiroshi Okamoto, Mikiko Shinozaki, Eisuke Inoue, Atsuo Taniguchi, Shigeki Momohara, Hisashi Yamanaka
  [show abstract] [hide abstract]
  ABSTRACT: OBJECTIVE: To investigate the point prevalence of major depressive disorder (MDD) as diagnosed by the Mini-International Neuropsychiatric Interview (M.I.N.I) in patients with rheumatoid arthritis (RA) and to determine whether MDD is related to features of RA disease, such as disease activity or physical dysfunction. METHODS: Of the patients with RA who participated in the IORRA survey conducted in October 2005, 162 were evaluated using the M.I.N.I., the Center for Epidemiologic Studies-Depression (CES-D) scale, and the two-question depression screen for MDD. RA clinical features were obtained from the concomitant IORRA cohort database. Relationships between MDD and RA disease features were analyzed by the Wilcoxon rank sum test and Pearson's chi-square test. RESULTS: The point prevalence of MDD as diagnosed by the M.I.N.I. was 6.8 % in our Japanese patients with RA. The percentage of depressive patients was determined to be 23.5, 17.3, or 7.4 % according to the CES-D scale with cut-off points of 16, 19, or 27, respectively, and 14.2 % according to the two-question depression screen. The best cut-off point for CES-D for risk of MDD diagnosed by M.I.N.I. in this study was determined to be 23, with 11.7 % depressive patients having the highest sum of sensitivity and specificity. No relationship between MDD and RA disease activity was detected. CONCLUSION: By using the well-established structural interview instrument M.I.N.I., we determined the point prevalence of MDD in the RA patients enrolled in this study to be 6.8 %, leading to the conclusion that concomitant MDD does not seem to influence disease activity in RA patients.
  Modern Rheumatology 05/2012; · 1.58 Impact Factor
• Article: Hyperferritinaemia and macrophage activation in a patient with interstitial lung disease with clinically amyopathic DM.

  Takahisa Gono, Kouhei Miyake, Yasushi Kawaguchi, Hirotaka Kaneko, Mikiko Shinozaki, Hisashi Yamanaka
  Rheumatology (Oxford, England) 02/2012; 51(7):1336-8. · 4.24 Impact Factor
• Article: Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis.

  Takahisa Gono, Yasushi Kawaguchi, Masako Hara, Ikuko Masuda, Yasuhiro Katsumata, Mikiko Shinozaki, Yuko Ota, Eri Ozeki, Hisashi Yamanaka
  [show abstract] [hide abstract]
  ABSTRACT: Acute/subacute interstitial pneumonia (A/SIP) is an intractable and fatal complication of DM. Since a useful indicator predicting the complication of A/SIP has not been found, the aim of this study was to determine whether serum ferritin is a potential predictive indicator of the occurrence of A/SIP in 64 patients with DM. Of the total patients enrolled, 19 had A/SIP, 24 had chronic interstitial pneumonia and 21 were without interstitial lung disease (ILD). Clinical manifestations and laboratory data were obtained from medical records on admission. Serum ferritin levels were extremely high in patients with DM with A/SIP. It was significantly higher in DM with A/SIP than that in DM without A/SIP (median 790 vs 186 ng/ml; P < 0.0001). The cumulative survival rate for 6 months was 62.7% in patients with DM with A/SIP. Moreover, the cumulative survival rate was significantly (P = 0.016) lower in the group with ferritin levels > or =1500 ng/ml than the rate in the group with ferritin levels <1500 ng/ml. Serum ferritin can be useful as a predictor of the occurrence of A/SIP and correlates with the prognosis of A/SIP in DM. The intensive treatment using combination therapy with various immunosuppressant agents should be chosen for patients with ILD with DM showing hyperferritinaemia, especially levels >1500 ng/ml.
  Rheumatology (Oxford, England) 04/2010; 49(7):1354-60. · 4.24 Impact Factor
• Article: Clinical images: Dramatic amelioration of pneumatosis cystoides intestinalis in systemic sclerosis.

  Yasuhiro Katsumata, Yuko Okamoto, Mikiko Shinozaki, Yasushi Kawaguchi, Hisashi Yamanaka
  Arthritis & Rheumatism 02/2010; 62(5):1468. · 7.87 Impact Factor
• Article: Clinical utility of computed tomographic scanning for the evaluation of lupus profundus in two patients with systemic lupus erythematosus.

  Takashi Kato, Ayako Nakajima, Tokiko Kanno, Mikiko Shinozaki, Takahisa Gono, Hisae Ichida, Ikuko Masuda, Naoyuki Kamatani, Masako Hara
  [show abstract] [hide abstract]
  ABSTRACT: Lupus profundus is a rare lupus-specific skin lesion with skin biopsies exhibiting lobular lymphocytic infiltration and destruction of subcutaneous fat tissue. In this report, a CT scan was effective in demonstrating both the presence and the extent of inflammation of lupus profundus in two patients with systemic lupus erythematosus (SLE). Case 1 was a 30-year-old woman developing erythema with subcutaneous induration on the upper arms during the quiescent phase of SLE. A skin biopsy confirmed a diagnosis of lupus profundus. A CT scan of the right upper arm demonstrated a high density area (HDA) of the subcutis under the erythema: a finding consistent with lupus profundus. Case 2 was a 28-year-old woman recently diagnosed with SLE. She also developed a skin ulcer on the right hip. A CT scan of the hip revealed an HDA and lipoatrophy of the subcutis around the ulcer: these findings were compatible with lupus profundus. Treatment with high-dose prednisolone improved the illness in the both cases. A CT scan is a useful and convenient imaging modality for confirming the diagnosis of lupus profundus.
  Modern Rheumatology 11/2008; 19(1):91-5. · 1.58 Impact Factor